Merck KGaA (ETR:MRK) Trading 0.5% Higher - Should You Buy?

Key Points

• Shares rose 0.5% intraday, last trading at €117.15 after reaching €118.40 on a volume of 292,655 shares (previous close €116.55).
• Valuation and financial snapshot: market cap $52.17B, P/E 19.24, PEG 2.37, beta 0.72, 50-/200-day SMAs €115.79/€117.83, debt-to-equity 41.86, current ratio 1.46 and quick ratio 0.72.
• Company profile: Merck KGaA is a Germany-based science and technology firm operating in Life Science, Healthcare and Electronics, with Life Science supplying tools, reagents and process technologies for biopharma and industrial customers.

Shares of Merck KGaA (ETR:MRK - ) traded up 0.5% during mid-day trading on Thursday . The stock traded as high as €118.40 and last traded at €117.15. 292,655 shares were traded during trading, The stock had previously closed at €116.55.

Merck KGaA Stock Performance

The company has a market capitalization of $52.17 billion, a price-to-earnings ratio of 19.24, a price-to-earnings-growth ratio of 2.37 and a beta of 0.72. The firm has a fifty day simple moving average of €115.79 and a 200 day simple moving average of €117.83. The company has a debt-to-equity ratio of 41.86, a current ratio of 1.46 and a quick ratio of 0.72.

About Merck KGaA

Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.